TP53 and cancer: In this regard, a correlation of p53 with immune checkpoint status has been clearly indicated since the presence of p53 mutations (eventually associated with KRAS (Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutant) in cancer patients has a potential predictive value on the response to anti-PD1 therapy [49].